ArticleOncotarget2017
Peiminine inhibits colorectal cancer cell proliferation by inducing apoptosis and autophagy and modulating key metabolic pathways.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Investigate the mechanisms of novel verticinone derivatives on lung cancer cell line (A549) by network pharmacology and transcriptome.Journal of traditional and complementary medicine · 2026Article
- Alkaloids from Fritillariae Cirrhosae Bulbus - progress on their pharmacological activities.Frontiers in pharmacology · 2026Review
- Fritillaria steroidal alkaloids and their multi-target therapeutic mechanisms: insights from network pharmacology.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Natural Products and Derivatives Targeting Metabolic Reprogramming in Colorectal Cancer: A Comprehensive Review.Metabolites · 2024Review
- Article
- Peiminine Exerts Its Anti-Acne Effects by Regulating the NF-κB Pathway.Antioxidants (Basel, Switzerland) · 2024Article
- Peiminine Enhances Doxorubicin Cytotoxicity and Downregulates hsa-miR-106a-5p and hsa -miR-181a-5p in Human Gastric Adenocarcinoma Cells.Advanced biomedical research · 2024Article
- Pyrazole-sulfonamide scaffold featuring dual-tail strategy as apoptosis inducers in colon cancer.Scientific reports · 2023Article
- Efficacy, chemical composition, and pharmacological effects of herbal drugs derived fromFrontiers in pharmacology · 2022Article
- Integrative analysis and identification of key elements and pathways regulated by Traditional Chinese Medicine (Yiqi Sanjie formula) in colorectal cancer.Frontiers in pharmacology · 2022Article
- Medicinal Plants for the Treatment of Gastrointestinal Cancers From the Metabolomics Perspective.Frontiers in pharmacology · 2022Review
- Bulbus Fritillariae Cirrhosae as a Respiratory Medicine: Is There a Potential Drug in the Treatment of COVID-19?Frontiers in pharmacology · 2021Review
- Molecular Characterization of Advanced Colorectal Cancer Using Serum Proteomics and Metabolomics.Frontiers in molecular biosciences · 2021Article
- Review
- Evaluation of the antitumor effects of PP242 in a colon cancer xenograft mouse model using comprehensive metabolomics and lipidomics.Scientific reports · 2020Article
- Identification of the Molecular Mechanisms of Peimine in the Treatment of Cough Using Computational Target Fishing.Molecules (Basel, Switzerland) · 2020Article
- A Systematic Review on Traditional Uses, Sources, Phytochemistry, Pharmacology, Pharmacokinetics, and Toxicity of Fritillariae Cirrhosae Bulbus.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- Phosphoproteomics Reveals Key Regulatory Kinases and Modulated Pathways Associated with Ovarian Cancer Tumors.OncoTargets and therapy · 2020Article
- Anti-Inflammatory Activity of Sanjie Zhentong Capsule Assessed By Network Pharmacology Analysis of Adenomyosis Treatment.Drug design, development and therapy · 2020Article
- Yiqi Chutan Tang Reduces Gefitinib-Induced Drug Resistance in Non-Small-Cell Lung Cancer by Targeting Apoptosis and Autophagy.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Peiminine, a compound extracted from the bulbs of Fritillaria thunbergii and traditionally used as a medication in China and other Asian countries, was reported to inhibit colorectal cancer cell proliferation and tumor growth by inducing autophagic cell death. However, its mechanism of anticancer action is not well understood, especially at the metabolic level, which was thought to primarily account for peiminine's efficacy against cancer. Using an established metabolomic profiling platform combining ultra-performance liquid chromatography/tandem mass spectrometry with gas chromatography/mass spectrometry, we identified metabolic alterations in colorectal cancer cell line HCT-116 after peiminine treatment. Among the identified 236 metabolites, the levels of 57 of them were significantly (p < 0.05) different between peiminine-treated and -untreated cells in which 45 metabolites were increased and the other 12 metabolites were decreased. Several of the affected metabolites, including glucose, glutamine, oleate (18:1n9), and lignocerate (24:0), may be involved in regulation of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway and in the oxidative stress response upon peiminine exposure. Peiminine predominantly modulated the pathways responsible for metabolism of amino acids, carbohydrates, and lipids. Collectively, these results provide new insights into the mechanisms by which peiminine modulates metabolic pathways to inhibit colorectal cancer cell growth, supporting further exploration of peiminine as a potential new strategy for treating colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.